Zydus Cadila has received the final approval from the USFDA to market Acetylcysteine Injection (US RLD - Acetadote Injection), 6 g/30 mL (200 mg/mL).

It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

In line with this, the group now has 211 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 6.1, or 1.76%, to trade at Rs 352.10. The total volume of shares traded was 8,406 at the BSE (9.27 a.m., Monday).